Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an MIR
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • AAAAI 2025

American Academy of Allergy, Asthma & Immunology (AAAAI): 81st Annual Meeting - 2025

February 28 – March 3, 2025

  1. All
  2. AIRSUPRA (albuterol/budesonide)
  3. FASENRA (benralizumab)
  4. TEZSPIRE (tezepelumab)

PDF

Asthma medication use before and after an asthma exacerbation: a US claims-based study

PDF

Effects on morning trough lung function with four times daily use of albuterol-budesonide versus albuterol over 1 weeks’ time: results from the DENALI study

PDF

A systematic literature review of real-world anti-interleukin-5 and anti-interleukin-5 receptor alpha treatment outcomes for hypereosinophilic syndrome: case reports and cohort studies

PDF

Patient journey to diagnosis of idiopathic hypereosinophilic syndrome (I-HES) or lymphocytic HES (L-HES) in the United States: evidence from a real-world retrospective observational cohort study

PDF

Treatment patterns in idiopathic hypereosinophilic syndrome (I-HES) or lymphocytic HES (L-HES) in the United States: a real-world retrospective observational cohort study

PDF

Two-year efficacy and safety of benralizumab for the treatment of eosinophilic granulomatosis with polyangiitis

PDF

Effect of tezepelumab on activity levels in patients with severe, uncontrolled asthma and chronic rhinosinusitis with nasal polyps in the phase 3 NAVIGATOR study

PDF

Effect of tezepelumab on fatigue in patients with severe, uncontrolled asthma and chronic rhinosinusitis with nasal polyps in the phase 3 NAVIGATOR study

HTML

Efficacy and safety of tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps: results from the phase 3 WAYPOINT study

PDF

Efficacy and safety of tezepelumab in adults with severe, uncontrolled asthma in Asia: results from the regional, phase 3 DIRECTION study

HTML

Efficacy of tezepelumab in patients with severe, uncontrolled asthma grouped by median baseline serum IL-5 and IL-13 levels: results from the phase 3 NAVIGATOR study

PDF

Substantial reduction in asthma exacerbations in patients with severe asthma with or without clinically relevant perennial allergy after 6 months of tezepelumab use: interim results from the phase 4 PASSAGE study

PDF

Asthma medication use before and after an asthma exacerbation: a US claims-based study

PDF

Effects on morning trough lung function with four times daily use of albuterol-budesonide versus albuterol over 1 weeks’ time: results from the DENALI study

PDF

A systematic literature review of real-world anti-interleukin-5 and anti-interleukin-5 receptor alpha treatment outcomes for hypereosinophilic syndrome: case reports and cohort studies

PDF

Patient journey to diagnosis of idiopathic hypereosinophilic syndrome (I-HES) or lymphocytic HES (L-HES) in the United States: evidence from a real-world retrospective observational cohort study

PDF

Treatment patterns in idiopathic hypereosinophilic syndrome (I-HES) or lymphocytic HES (L-HES) in the United States: a real-world retrospective observational cohort study

PDF

Two-year efficacy and safety of benralizumab for the treatment of eosinophilic granulomatosis with polyangiitis

PDF

Effect of tezepelumab on activity levels in patients with severe, uncontrolled asthma and chronic rhinosinusitis with nasal polyps in the phase 3 NAVIGATOR study

PDF

Effect of tezepelumab on fatigue in patients with severe, uncontrolled asthma and chronic rhinosinusitis with nasal polyps in the phase 3 NAVIGATOR study

HTML

Efficacy and safety of tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps: results from the phase 3 WAYPOINT study

PDF

Efficacy and safety of tezepelumab in adults with severe, uncontrolled asthma in Asia: results from the regional, phase 3 DIRECTION study

HTML

Efficacy of tezepelumab in patients with severe, uncontrolled asthma grouped by median baseline serum IL-5 and IL-13 levels: results from the phase 3 NAVIGATOR study

PDF

Substantial reduction in asthma exacerbations in patients with severe asthma with or without clinically relevant perennial allergy after 6 months of tezepelumab use: interim results from the phase 4 PASSAGE study

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 3/26

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data 
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States